Litcius/Paper detail

Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy

Maria Mortoglou, Zoey Kathleen Tabin, Elif Damla Arısan, Hemant M. Kocher, Pinar Uysal‐Onganer

2021Translational Oncology35 citationsDOIOpen Access PDF

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with a 5-year survival rate less than 8%, which has remained unchanged over the last 50 years. Early detection is particularly difficult due to the lack of disease-specific symptoms and a reliable biomarker. Multimodality treatment including chemotherapy, radiotherapy (used sparingly) and surgery has become the standard of care for patients with PDAC. Carbohydrate antigen 19-9 (CA 19-9) is the most common diagnostic biomarker; however, it is not specific enough especially for asymptomatic patients. Non-coding RNAs are often deregulated in human malignancies and shown to be involved in cancer-related mechanisms such as cell growth, differentiation, and cell death. Several micro, long non-coding and circular RNAs have been reported to date which are involved in PDAC. Aim of this review is to discuss the roles and functions of non-coding RNAs in diagnosis and treatments of PDAC.

Topics & Concepts

BiomarkerMedicineRadiation therapyPancreatic ductal adenocarcinomaAsymptomaticPancreatic cancerDiseaseLong non-coding RNAAdenocarcinomaOncologyBioinformaticsCancer researchCancerInternal medicineGeneRNABiologyBiochemistryCancer-related molecular mechanisms researchCircular RNAs in diseasesRNA modifications and cancer
Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy | Litcius